Trospium Chloride, Xanomeline Tartrate

• A one-year study to assess if Xanomeline/Trospium (XT) can improve cognitive function in adults living with schizophrenia. Not authorised
  2025-523060-20-00 Phase III 9 countries European Group for Research in Schizophrenia Stichting
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 Phase III 11 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending
  2025-523711-11-00 Phase III 1 country Bristol-Myers Squibb Services Unlimited Company
• Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending
  2025-524062-16-00 Phase III 1 country Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting
  2025-521845-26-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520746-30-00 Phase III 8 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520195-94-00 Phase III 5 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520259-26-00 Phase III 9 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520612-34-00 Phase III 5 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520165-32-00 Phase III 3 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520613-31-00 Phase III 6 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520747-32-00 Phase III 10 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease Recruiting
  2024-516363-92-00 Phase III 13 countries Bristol-Myers Squibb Services Unlimited Company
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting
  2023-504151-27-00 Phase III 14 countries Karuna Therapeutics Inc.
• A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with … Ended
  2024-510773-20-00 Phase III 1 country Karuna Therapeutics Inc.
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) Ended
  2024-510770-25-00 Phase III 1 country Karuna Therapeutics Inc.

Showing 1–16 of 16 trials